1152552-07-2Relevant academic research and scientific papers
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold
Galatsis, Paul,Henderson, Jaclyn L.,Kormos, Bethany L.,Han, Seungil,Kurumbail, Ravi G.,Wager, Travis T.,Verhoest, Patrick R.,Noell, G. Stephen,Chen, Yi,Needle, Elie,Berger, Zdenek,Steyn, Stefanus J.,Houle, Christopher,Hirst, Warren D.
, p. 4132 - 4140 (2014)
Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the str
COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 125, (2018/06/12)
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
A Convenient One-Pot Synthesis of Triazolopyridine and Related Heterocycle Fused-Triazole Analogs Through Copper Catalyzed Oxidative Cyclization Strategy
Srinivasan,Sembian Ruso,Nagarajan,Senthil Kumaran,Manickam
, p. 606 - 614 (2016/04/19)
One-pot synthesis of heterocycle fused-triazole analogs from the corresponding aldehydes and heteroarylhydrazines is demonstrated. Transformation of hydrazones to the desired systems was achieved by employing the oxidative cyclization with catalytic CuBr2 and oxone. This reaction condition is mild and selective, and a wide range of functional groups were able to sustain. An array of biologically important triazolopyridines, triazolopyridazines, triazolopyrimidines, and triazoloquinolines were obtained in fairly good yield.
Triazolopyridazine LRRK2 kinase inhibitors
Franzini, Maurizio,Ye, Xiaocong M.,Adler, Marc,Aubele, Danielle L.,Garofalo, Albert W.,Gauby, Shawn,Goldbach, Erich,Probst, Gary D.,Quinn, Kevin P.,Santiago, Pam,Sham, Hing L.,Tam, Danny,Truong, Anh,Ren, Zhao
, p. 1967 - 1973 (2013/04/24)
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [
